Because you care, little miss peek-a-boo has the protection of the only DTaP-IPV/Hiba vaccine
aDTaP = Diphtheria, tetanus, and acellular pertussis;
IPV = Inactivated poliovirus; Hib = Haemophilus influenzae type b.
IMPORTANT SAFETY INFORMATION
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).
The most common local and systemic adverse reactions to Pentacel vaccine include redness, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. Other adverse reactions may occur. A known hypersensitivity (eg, anaphylaxis) to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.
The decision to give Pentacel vaccine should be based on careful consideration of the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to a previous dose of Pentacel vaccine or receipt of any other tetanus toxoid, diphtheria toxoid, or pertussis antigen-containing vaccine. Apnea following intramuscular vaccination has been observed in some infants born prematurely. Encephalopathy within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals.
Before administering Pentacel vaccine, please see accompanying full Prescribing Information.
Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.